Recent Updates — FTH

The Board of Directors increased its size from six to seven directors and appointed Adam Schayowitz as a Class III director, effective October 23, 2026. Dr. Schayowitz brings extensive experience in oncology drug development and clinical strategy from roles at Zymeworks, Pfizer, and Tesaro. In connection with his appointment, he will receive a cash retainer and an initial equity award consisting of options to purchase 25,000 shares under the Company’s 2026 Equity Incentive Plan. The options vest in equal monthly installments over three years. Faeth Therapeutics operates as a clinical-stage biotechnology company focused on developing novel therapies for cancer.

Faeth Therapeutics, Inc. appointed Karen Vousden, Ph.D., as a Class II director effective September 11, 2026, increasing the Board size from five to six members. Dr. Vousden, a co-founder and cancer biologist with extensive experience at The Francis Crick Institute and Cancer Research UK, will also serve on the Compensation Committee. Her appointment includes an initial equity grant of options for 25,000 shares vesting over three years. Faeth Therapeutics is a biopharmaceutical company focused on developing therapies targeting p53-related cancers.